Clinical Trials Browser

dostarlimab × Gastrointestinal × 90 days × Clear all

Carcinoma, Hepatocellular

NCT06567782 2026-04-02

AZUR-4

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Colonic Neoplasms

NCT05277051 2026-03-23

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

152 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06830239 2026-02-12

Superhero

Phase 2 Recruiting

10 enrolled

Gastrointestinal

Colonic Neoplasms

NCT07381777 2026-02-02

IMMUNOSTAR

Phase 2 Not yet recruiting

270 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT04165772 2026-01-23

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2 Recruiting

200 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Phase 3 Recruiting

892 enrolled

Gastrointestinal

Colonic Neoplasms

Clinical Trials

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

AZUR-4

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Superhero

IMMUNOSTAR

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer